Sermorelin

1. What is it?

Sermorelin is a synthetic peptide corresponding to the active fragment of natural growth hormone-releasing hormone, known as GHRH. It consists of 29 amino acids. It is not growth hormone itself: it is intended to stimulate its secretion by the pituitary, a small gland at the base of the brain. The distinction matters because successful stimulation depends on whether the pituitary retains the ability to respond. Similar-sounding names of other peptides do not mean identical effects. [66] [86]

2. Why do people turn to it?

Sermorelin also attracts interest in relation to muscles, recovery and age-related changes. These expectations stem from its effect on growth hormone. However, its best-described medical use concerned growth disorders in children. That history should not be presented as evidence of rejuvenation in healthy adults. [65] [66]

The former medicine Geref was indicated for a selected group of children with idiopathic growth hormone deficiency and impaired growth. Here, idiopathic means that no specific cause has been established. A separate diagnostic preparation was used to test the pituitary response. These were not indications for treating ordinary fatigue or natural age-related changes. Not every case of short stature is caused by GH deficiency, as separate studies in short children with normal secretion of the hormone also show. [65] [68]

3. How does it work?

Stimulation of the pituitary gland increases release of GH, or growth hormone. Some of its later effects involve IGF-1, a substance that contributes to tissue growth, among other functions. A hormone test result alone does not show whether a person functions better. In studies of children, actual growth rate and bone maturation were more meaningful measures. In adults, physical functioning, symptoms and adverse effects would need separate assessment, rather than treating higher GH as a benefit in itself. [66] [67]

4. What do studies actually show?

A multicentre study from 1996 treated 110 prepubertal children with GH deficiency; 86 met the criteria for the effectiveness analysis. Average growth rate was 4.1 cm per year before treatment and 7.2 cm per year after one year. This was an open-label study, meaning treatment was not concealed from participants or the team. An earlier paper from 1987 also described improved growth in some treated children, while showing that not everyone responded in the same way. [66] [67]

5. What do we still not know?

Findings in a growing child with a hormonal disorder do not answer what happens in a healthy adult. Brief GH stimulation does not establish fat loss, faster injury healing or longer life. A small study in short children with normal GH concerns another situation and does not justify these conclusions either. Documented paediatric use must be separated from broad recovery promises. [66] [68]

6. What are the risks?

In a one-year children's study, authors reported good overall tolerability and no adverse changes in monitored biochemical measures. This informs us about that study, not safety at every age or for any duration. The FDA analysis also notes that eligibility for the former treatment included assessing pituitary response. Data from such a selected group cannot be applied to self-directed use without diagnosed deficiency. [66] [86]

In sport governed by WADA anti-doping rules, this substance is prohibited at all times, including outside competition. The 2026 list names it explicitly. Use during training or a break between competitions is also covered by the ban. [108]

7. Is it an approved medicine?

Geref had US diagnostic and treatment approvals, but sales ceased and approvals were withdrawn in 2009. In 2013, FDA determined this was not for safety or effectiveness reasons. That does not make every subsequent sermorelin product an approved equivalent. It describes the US situation, not authorization or product information for a particular medicine in Poland. [65]

8. What is new in research?

The source review completed on 3 November 2026 found no new large primary study confirming anti-ageing benefits of sermorelin in healthy adults. Historical growth studies and Geref documentation remain the main reference points. Future reports should be checked for who was treated and whether a noticeable health improvement was measured. A new description of an old mechanism is not a new treatment result. [66] [65]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.